Home Newsfeeds Goldman Sachs Downgrades Parkland to Sell

Goldman Sachs Downgrades Parkland to Sell

Goldman Sachs analyst Neil Mehta downgrades Parkland (TSX:PKI) from Neutral to Sell.

byBenzinga Newsdesk

July 13, 2022

1 minute read

Goldman Sachs analyst Neil Mehta downgrades Parkland (TSX:PKI) from Neutral to Sell.

Analyst Ratings

What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals

By Benzinga Insights

January 3, 2:00 PM

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

APLS

Tim Seymour On Running A Cannabis Fund: ‘We Focus On Companies Poised For Growth’

By Nicolas Jose Rodriguez

June 17, 9:26 AM

Tim Seymour, portfolio manager of the $CNBS Amplify Seymour Cannabis ETF (NYSE: CNBS), is renowned for recognizing the potential of the cannabis sector early on.

BTI

Chimerix Announces Data Highlighting Clinical Efficacy And Molecular Mechanisms Of Response To ONC201 Treatment Of H3 K27M-Mutant Diffuse Midline Gliomas Published In “Cancer Discovery”

By Happy Mohamed

August 16, 10:07 AM

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic

CMRX